Menu
Back to User profile » Dr Keiko Hosohata
Papers published by Dr Keiko Hosohata:
Risk Factors for COVID-19 Infection in Adult Patients: A Retrospective Observational Study in Japan
Yoshida A, Furumachi K, Kumagai E, Hosohata K
Infection and Drug Resistance 2024, 17:441-448
Published Date: 3 February 2024
A Pharmacovigilance Study of Drug-Induced Glaucoma Utilizing the Japanese Adverse Event Reporting System
Kozaru M, Iida T, Hosohata K
Clinical Ophthalmology 2023, 17:3645-3653
Published Date: 29 November 2023
Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database
Hata T, Hirata A, Ota R, Hosohata K, Nishihara M, Neo M, Katsumata T
Therapeutics and Clinical Risk Management 2022, 18:843-853
Published Date: 24 August 2022
Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database
Wakabayashi T, Hosohata K, Oyama S, Inada A, Ueno S, Kambara H, Iida T, Nakatsuji T, Uchida M, Iwanaga K
Therapeutics and Clinical Risk Management 2020, 16:741-747
Published Date: 13 August 2020
Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database
Inada A, Hosohata K, Oyama S, Niinomi I, Mori Y, Yamaguchi Y, Uchida M, Iwanaga K
Therapeutics and Clinical Risk Management 2019, 15:59-64
Published Date: 24 December 2018
Drug-induced tubulointerstitial nephritis in a retrospective study using spontaneous reporting system database
Oyama S, Hosohata K, Inada A, Niinomi I, Mori Y, Yamaguchi Y, Uchida M, Iwanaga K
Therapeutics and Clinical Risk Management 2018, 14:1599-1604
Published Date: 5 September 2018